Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Ypsomed Holding AG (YPSN.SW)
CHF366.60
-1.40 (-0.38%)
CH SIX Healthcare Medical - Specialties
Address
Brunnmattstrasse 6 3401
Burgdorf, BE, CH
Burgdorf, BE, CH
CEO
Simon Michel
Website
ypsomed.com
IPO
2004-09-22
ISIN CH0019396990
Also trades on
London Stock Exchange · 0QLQ.L (CHF)
Other OTC · YPHDF (USD)
Swiss Exchange · YPSN.SW (CHF)
Description
Ypsomed Holding AG, together with its subsidiaries, develops, manufactures, and sells injection and infusion systems for safe and simple self-medication companies. The company operates through three segments: Ypsomed Delivery Systems, Ypsomed Diabetes Care, and Others. The Ypsomed Delivery Systems segment provides various injection systems, such as pen injectors, auto-injectors, and wearable injectors, as well as other smart devices. This segment offers its products under the YDS brand. The Ypsomed Diabetes Care segment sells and trades in insulin pumps, infusion sets, pen needles, blood glucose monitoring systems, accessories, and other day-to-day items for diabetics. This segment offers its products under the mylife brand name. The company offers precision turned parts; and contract manufacturing and other services. It markets its products through pharmaceutical partners, as well as through its own distribution network and independent distributors. It operates in Switzerland, Europe, North America, and internationally. Ypsomed Holding AG was founded in 1984 and is headquartered in Burgdorf, Switzerland.
Market Cap & Enterprise Value
Merger & Acquisition History
No mergers or acquisitions recorded for this company.
Technical Outlook
Loading outlook…
Loading forecast...
Signal Summary
Loading…
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Each column is computed on that timeframe's candles (1D = daily, 1W ≈ weekly, 1M ≈ monthly), not on the same last day. ▲ bullish · ▼ bearish · — neutral. The Net row counts signals per column; hover any cell (or the indicator name) to see the exact rule behind it.
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
Indicative levels generated algorithmically. Not financial advice.
Risk Profile
Loading risk profile…
Price Chart
CHF366.60
-1.40 (-0.38%)
Loading historical data…
Volume Profile
Loading…
Liquidity & share structure
Average Volume
18.5K
Beta
0.78
Float Shares
3.98M
Free Float %
30.3%
Price Performance
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| +3.91% | +15.25% | +20.82% | +25.23% | +2.41% | +3.66% | -11.92% | +50.44% | +137.17% | +113.15% | +354.73% |
Rolling Volatility
Loading…
Drawdown
Loading…
Relative Strength
Loading…
Monthly Returns Heatmap
From
To
Loading…
Annual Monthly Returns
Loading…
Daily Returns Distribution
Loading histogram data…
Revenue flow
Revenue by geography
Revenue by segment
From
To
Revenue composition
From
To
By product
By geography
Financial Statements
Select metrics from the tables below to build your comparison.
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
Price Targets & DCF
Current price
366.60
Ratings Trend (MoM)
83% Bullish
| Rating | 2026-05 | Change |
|---|---|---|
| Strong Buy | 3 | +1 |
| Buy | 7 | +1 |
| Hold | 1 | -1 |
| Sell | 0 | 0 |
| Strong Sell | 1 | 0 |
Quality scores
Altman Z-Score
7.06
Safe zone
Piotroski F-Score
8 / 9
Strong
MOAT Score
3 / 10
No MOAT
Composite Rating
D+
Overall Score
1 / 5
Low
DCF Score
1 / 5
Low
ROE Score
1 / 5
Low
ROA Score
1 / 5
Low
D/E Score
2 / 5
Medium
P/E Score
1 / 5
Low
P/Book Score
1 / 5
Low
Operational MOAT
✗ Below peers
-
Revenue growth Medical - Specialties: +8.3%-2.4% Q1'26: +127.3% (vs Q3'24)
-
EPS growth Medical - Specialties: +10.1%+154.3% ★ Q1'26: +155.6% (vs Q3'24)
-
FCF margin FCF growth · Medical - Specialties: +51.3%+37.3% ★ Q1'26: +1.9% (vs Q3'24)
-
EBIT margin Medical - Specialties: +12.6%+33.4% ★ Q1'26: +29.8% (vs Q3'24)
-
ROIC Medical - Specialties: +6.6%+22.9% ★ Q1'26: +39.5% (vs Q3'24)
-
Share dilution Medical - Specialties: 0.0%-0.3% ★ Q1'26: -0.7% (vs Q3'24)
-
Debt / EBITDA Net debt/EBITDA · Medical - Specialties: -0.39×0.80× Q1'26: 0.42× (vs Q3'24)
Valuation Multiples
From
To
Price Forecast (3Y)
From
To
Theoretical Return — If Invested Today
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
Consensus Estimates
| Metric |
Mar 2011 actual |
Mar 2012 actual |
Mar 2013 actual |
Mar 2014 actual |
Mar 2015 actual |
Mar 2016 actual |
Mar 2017 actual |
Mar 2018 actual |
Mar 2019 actual |
Mar 2020 actual |
Mar 2021 actual |
Mar 2022 actual |
Mar 2023 actual |
Mar 2024 actual |
Mar 2025 actual |
Mar 2026 10 Rev. Ana. 9 EPS Ana. |
Mar 2027 4 Rev. Ana. 7 EPS Ana. |
Mar 2028 8 Rev. Ana. 8 EPS Ana. |
Mar 2029 5 Rev. Ana. 4 EPS Ana. |
Mar 2030 2 Rev. Ana. 2 EPS Ana. |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue |
242.46M
est: 252.15M (-3.8%)
|
248.59M
est: 261.92M (-5.1%)
|
244.57M
est: 264.20M (-7.4%)
|
276.26M
est: 277.34M (-0.4%)
|
306.63M
est: 303.00M (+1.2%)
|
336.92M
est: 335.10M (+0.5%)
|
389.56M
est: 391.15M (-0.4%)
|
466.12M
est: 461.10M (+1.1%)
|
453.77M
est: 378.00M (+20.0%)
|
394.26M
est: 397.00M (-0.7%)
|
403.66M
est: 403.92M (-0.1%)
|
464.84M
est: 462.02M (+0.6%)
|
497.46M
est: 512.80M (-3.0%)
|
548.46M
est: 581.70M (-5.7%)
|
748.87M
est: 671.02M (+11.6%)
|
720.45M
675.27M – 735.76M
+7.4% YoY
|
709.76M
704.51M – 712.64M
-1.5% YoY
|
805.55M
766.45M – 850.96M
+13.5% YoY
|
911.49M
910.37M – 912.62M
+13.2% YoY
|
1.01B
980.44M – 1.04B
+10.8% YoY
|
| EBITDA |
33.91M
est: 35.60M (-4.8%)
|
36.98M
est: 31.36M (+17.9%)
|
29.32M
est: 39.60M (-26.0%)
|
35.32M
est: 28.72M (+23.0%)
|
47.41M
est: 42.44M (+11.7%)
|
64.64M
est: 51.15M (+26.4%)
|
86.56M
est: 81.08M (+6.8%)
|
97.08M
est: 98.05M (-1.0%)
|
115.59M
est: 91.22M (+26.7%)
|
61.63M
est: 103.86M (-40.7%)
|
65.19M
est: 63.56M (+2.6%)
|
96.66M
est: 73.20M (+32.0%)
|
137.51M
est: 81.18M (+69.4%)
|
161.56M
est: 90.78M (+78.0%)
|
190.90M
est: 201.61M (-5.3%)
|
213.30M
199.92M – 217.83M
+5.8% YoY
|
210.13M
208.58M – 210.99M
-1.5% YoY
|
238.49M
226.92M – 251.94M
+13.5% YoY
|
269.86M
269.53M – 270.19M
+13.2% YoY
|
299.02M
290.27M – 308.55M
+10.8% YoY
|
| EBIT |
8.83M
est: 13.01M (-32.1%)
|
10.52M
est: 8.93M (+17.8%)
|
3.96M
est: 5.14M (-23.1%)
|
15.54M
est: 3.88M (+300.2%)
|
26.95M
est: 18.70M (+44.1%)
|
44.25M
est: 29.46M (+50.2%)
|
55.73M
est: 51.33M (+8.6%)
|
62.28M
est: 67.24M (-7.4%)
|
70.47M
est: 57.23M (+23.1%)
|
8.64M
est: 66.69M (-87.1%)
|
9.17M
est: 10.74M (-14.6%)
|
28.58M
est: 12.37M (+131.0%)
|
58.73M
est: 13.72M (+328.1%)
|
86.69M
est: 15.34M (+465.1%)
|
110.96M
est: 111.71M (-0.7%)
|
118.18M
110.77M – 120.70M
+5.8% YoY
|
116.43M
115.57M – 116.90M
-1.5% YoY
|
132.14M
125.73M – 139.59M
+13.5% YoY
|
149.52M
149.34M – 149.71M
+13.2% YoY
|
165.68M
160.83M – 170.96M
+10.8% YoY
|
| Net Income |
5.21M
est: 9.12M (-42.9%)
|
8.50M
est: 5.40M (+57.4%)
|
1.65M
est: 8.57M (-80.8%)
|
13.61M
est: 1.68M (+710.2%)
|
19.40M
est: 15.14M (+28.1%)
|
35.81M
est: 21.31M (+68.1%)
|
46.25M
est: 41.79M (+10.7%)
|
52.06M
est: 54.11M (-3.8%)
|
60.14M
est: 48.90M (+23.0%)
|
11.73M
est: 55.68M (-78.9%)
|
5.81M
est: 12.59M (-53.8%)
|
23.11M
est: 14.50M (+59.4%)
|
51.28M
est: 51.28M (+0.0%)
|
78.37M
est: 78.37M (+0.0%)
|
87.50M
est: 106.71M (-18.0%)
|
221.93M
106.06M – 232.85M
+108.0% YoY
|
176.31M
135.26M – 189.50M
-20.6% YoY
|
207.52M
183.28M – 233.61M
+17.7% YoY
|
232.84M
224.14M – 263.07M
+12.2% YoY
|
279.57M
268.93M – 291.15M
+20.1% YoY
|
| SGA |
50.37M
est: 48.44M (+4.0%)
|
53.33M
est: 52.35M (+1.9%)
|
54.12M
est: 53.76M (+0.7%)
|
55.41M
est: 56.79M (-2.4%)
|
60.21M
est: 61.65M (-2.3%)
|
62.20M
est: 66.16M (-6.0%)
|
72.88M
est: 72.58M (+0.4%)
|
82.10M
est: 85.26M (-3.7%)
|
90.09M
est: 77.13M (+16.8%)
|
89.16M
est: 83.42M (+6.9%)
|
94.06M
est: 98.00M (-4.0%)
|
89.42M
est: 112.87M (-20.8%)
|
103.29M
est: 125.17M (-17.5%)
|
107.99M
est: 139.98M (-22.9%)
|
125.54M
est: 161.19M (-22.1%)
|
127.89M
119.87M – 130.60M
-20.7% YoY
|
125.99M
125.06M – 126.50M
-1.5% YoY
|
142.99M
136.05M – 151.05M
+13.5% YoY
|
161.80M
161.60M – 162.00M
+13.2% YoY
|
179.28M
174.04M – 185.00M
+10.8% YoY
|
| EPS |
0.43
est: 0.49 (-11.8%)
|
0.67
est: 1.06 (-36.5%)
|
0.13
est: 1.12 (-88.4%)
|
1.08
est: 0.79 (+37.5%)
|
1.54
est: 1.62 (-5.2%)
|
2.84
est: 2.63 (+8.1%)
|
3.67
est: 3.67 (+0.0%)
|
4.14
est: 4.06 (+2.0%)
|
4.77
est: 1.61 (+197.2%)
|
0.93
est: 0.47 (+97.4%)
|
0.46
est: 0.83 (-44.9%)
|
1.83
est: 1.84 (-0.5%)
|
3.82
est: 3.35 (+14.0%)
|
5.74
est: 5.66 (+1.5%)
|
6.41
est: 7.86 (-18.4%)
|
13.12
7.79 – 17.11
+67.0% YoY
|
13.00
9.94 – 13.93
-0.9% YoY
|
15.21
13.47 – 17.17
+17.0% YoY
|
17.84
16.47 – 19.33
+17.3% YoY
|
20.55
19.76 – 21.40
+15.1% YoY
|
Historical Ratings (3M)
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-22 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 1/5 |
| 2026-05-21 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 1/5 |
| 2026-05-20 | B | 3/5 | 1/5 | 5/5 | 5/5 | 3/5 | 2/5 | 1/5 |
| 2026-05-19 | B | 3/5 | 1/5 | 5/5 | 5/5 | 3/5 | 2/5 | 1/5 |
| 2026-05-18 | B | 3/5 | 1/5 | 5/5 | 5/5 | 3/5 | 2/5 | 1/5 |
| 2026-05-15 | B+ | 3/5 | 1/5 | 5/5 | 5/5 | 3/5 | 2/5 | 2/5 |
| 2026-05-13 | B+ | 3/5 | 1/5 | 5/5 | 5/5 | 3/5 | 2/5 | 2/5 |
| 2026-05-12 | B+ | 3/5 | 1/5 | 5/5 | 5/5 | 3/5 | 2/5 | 2/5 |
| 2026-05-11 | B+ | 3/5 | 1/5 | 5/5 | 5/5 | 3/5 | 2/5 | 2/5 |
| 2026-05-08 | B+ | 3/5 | 1/5 | 5/5 | 5/5 | 3/5 | 3/5 | 2/5 |
| 2026-05-07 | B+ | 3/5 | 1/5 | 5/5 | 5/5 | 3/5 | 3/5 | 2/5 |
| 2026-05-06 | B+ | 3/5 | 1/5 | 5/5 | 5/5 | 3/5 | 3/5 | 2/5 |
| 2026-05-05 | B+ | 3/5 | 1/5 | 5/5 | 5/5 | 2/5 | 3/5 | 2/5 |
| 2026-05-04 | B+ | 3/5 | 1/5 | 5/5 | 5/5 | 2/5 | 3/5 | 2/5 |
| 2026-04-30 | B+ | 3/5 | 1/5 | 5/5 | 5/5 | 2/5 | 3/5 | 2/5 |
| 2026-04-29 | B+ | 3/5 | 1/5 | 5/5 | 5/5 | 2/5 | 3/5 | 2/5 |
| 2026-04-28 | B+ | 3/5 | 1/5 | 5/5 | 5/5 | 2/5 | 3/5 | 2/5 |
| 2026-04-27 | B+ | 3/5 | 1/5 | 5/5 | 5/5 | 2/5 | 3/5 | 2/5 |
| 2026-04-24 | B+ | 3/5 | 1/5 | 5/5 | 5/5 | 2/5 | 3/5 | 2/5 |
| 2026-04-23 | B+ | 3/5 | 1/5 | 5/5 | 5/5 | 2/5 | 3/5 | 2/5 |
| 2026-04-22 | B+ | 3/5 | 1/5 | 5/5 | 5/5 | 2/5 | 3/5 | 2/5 |
| 2026-04-21 | B+ | 3/5 | 1/5 | 5/5 | 5/5 | 2/5 | 3/5 | 2/5 |
| 2026-04-20 | B+ | 3/5 | 1/5 | 5/5 | 5/5 | 2/5 | 3/5 | 2/5 |
| 2026-04-17 | B+ | 3/5 | 1/5 | 5/5 | 5/5 | 2/5 | 3/5 | 2/5 |
| 2026-04-16 | B+ | 3/5 | 1/5 | 5/5 | 5/5 | 2/5 | 3/5 | 2/5 |
Owner Earnings
Owner's Earnings (history)
From
To
Owner alignment
Owner's Earnings TTM
313.27M
OE per share TTM
23.03
Owner's Yield
6.80%
Maintenance CapEx ratio
2.95%
Maint CapEx / Avg PPE
83.2%
Ownership Overview
Ownership breakdown
Ownership breakdown not available.
At a glance
Institutional holders
—
Total invested
—
Insider transactions (90d)
0
Beneficial owners (>5%)
0
Beneficial owners (>5%)
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional ownership trend
Institutional history not available.
Top institutional holders
Top holders not available.
ETF Ownership
Top ETFs holding this stock
Held by 83 ETFs in our universe
| # | ETF | Weight | Est. AUM exposure | TER |
|---|---|---|---|---|
| 1 | First Trust Switzerland AlphaDEX Fund FSZ | 1.75% | 647.4K | 0.80% |
| 2 | Global X - Aging Population ETF AGNG | 0.41% | 355.4K | 0.50% |
| 3 | iShares International Developed Small Cap Value Factor ETF ISVL | 0.25% | 778.7K | 0.31% |
| 4 | Amundi MSCI Europe Small Cap ESG Broad Transition UCITS ETF Dist X026.DE | 0.16% | 564.7K | 0.23% |
| 5 | Amundi MSCI Europe Small Cap ESG Broad Transition UCITS ETF Acc CEM.PA | 0.16% | 564.7K | 0.23% |
| 6 | Xtrackers MSCI Europe Small Cap UCITS ETF 1C XXSC.L | 0.12% | 4.07M | 0.30% |
| 7 | iShares MSCI Europe Small-Cap ETF IEUS | 0.12% | 206.8K | 0.41% |
| 8 | Goldman Sachs Innovate Equity ETF GINN | 0.11% | 228.8K | 0.50% |
| 9 | iShares $ Treasury Bond 3-7yr UCITS ETF CBUG.DE | 0.08% | 343.1K | 0.10% |
| 10 | iShares Core SPI(R) ETF (CH) CHSPI.SW | 0.08% | 5.34M | 0.10% |
Insider Activity
Insider Activity — Latest Quarter
No insider activity available.
Insider buys vs sells (history)
Insider history not available.
Recent insider transactions
No recent insider transactions.
Executive team
Top executives
EBIT / Employee
119.6K
Shares Outstanding
13.15M
Executive compensation
Executive compensation (annual)
Executive compensation not available.
CEO compensation breakdown
No CEO compensation history available.
Proxy statements
Proxy statements (DEF 14A)
No proxy statements available for this company yet.
Recent SEC filings
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Simon Michel | CEO, Member of Executive Board & Member of the Board | 1M | male |
| Michael Zaugg | Chief Corporate Officer & Member of Executive Board | — | male |
| Nicolas Meyer | Chief Legal Officer & Secretary and Member of Executive Board | — | — |
| Frank Mengis | COO, Deputy CEO Member of Executive Board | — | male |
| Samuel Kunzli | Chief Financial Officer & Member of Executive Board | — | male |
| Ulrike Bauer | Chief Business Officer & Member of Executive Board | — | female |
| Sam Ghezelbash | Head of Investor Relations & M&A | — | — |
ESG Score History
No data available for this company.
Senate Trading Activity
No Senate trading activity found for this company.
House Trading Activity
No House trading activity found for this company.
Market share among peers
Peer comparison — filtered group (TTM)
Your opinion
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for YPSN.SW
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
